Novel cholesterol lowering drugs: Can phase 2/3 clinical trial safety assessments predict cardiovascular event outcome trial efficacy?

Am Heart J Plus · 2026 · PMC12908039 · PMID 41704227

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a clear trendno p-value reported

However, the very limited non-CVOT data that has been published,does not show a clear trend for MACE imbalance in favor of the drug (see Table 3 ).

also in 19,460 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.